KALA BIO Files 8-K on Shareholder Vote Matters

TL;DR

KALA BIO holding shareholder vote on June 11th, filing 8-K today.

AI Summary

KALA BIO, Inc. filed an 8-K on June 12, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2024. The company, formerly known as Kala Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Arlington, MA.

Why It Matters

This filing indicates that KALA BIO, Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction or financial structure.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Numbers

• 001-38150 — SEC File Number (Identifies the company's filing history with the SEC.)
• 27-0604595 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• KALA BIO, Inc. (company) — Registrant
• Kala Pharmaceuticals, Inc. (company) — Former Company Name
• June 11, 2024 (date) — Date of earliest event reported
• June 12, 2024 (date) — Date of Report
• Arlington, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq

Filing Documents

• kala-20240611x8k.htm (8-K) — 84KB
• 0001558370-24-009093.txt ( ) — 199KB
• kala-20240611.xsd (EX-101.SCH) — 3KB
• kala-20240611_lab.xml (EX-101.LAB) — 15KB
• kala-20240611_pre.xml (EX-101.PRE) — 9KB
• kala-20240611x8k_htm.xml (XML) — 5KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Stockholders of KALA BIO, Inc. (the "Company") held on June 11, 2024 (the "Annual Meeting"), the Company's stockholders voted on the proposals set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 29, 2024. 1. The Company's stockholders elected Marjan Farid, M.D., Andrew I. Koven and Gregory D. Perry as Class I directors, each to serve for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non- Votes Marjan Farid, M.D. 982,896 31,108 847,128 Andrew I. Koven 866,235 147,769 847,128 Gregory D. Perry 982,184 31,820 847,128 2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to the compensation paid to the Company's named executive officers were as follows: Votes For Votes Against Votes Abstaining Broker Non- Votes 764,305 225,459 24,240 847,128 3. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders' vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non- Votes 1,825,140 21,748 14,244 0 4. The Company's stockholders approved the issuance of shares of the Company's common stock upon conversion of the Company's Series E Convertible Non-Redeemable Preferred Stock, Series F Convertible Non-Red

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: June 12, 2024 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR